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Abstract The deposition of L-amyloid peptide (AL), the
hyperphosphorylation of tau protein and the death of neurons
in certain brain regions are characteristic features of Alzheimer’s
disease. It has been proposed that the accumulation of aggregates
of AL is the trigger of neurodegeneration in this disease. In
support of this view, several studies have demonstrated that the
treatment of cultured neurons with AL leads to the hyper-
phosphorylation of tau protein and neuronal cell death. Here we
report that lithium prevents the enhanced phosphorylation of tau
protein at the sites recognized by antibodies Tau-1 and PHF-1
which occurs when cultured rat cortical neurons are incubated
with AL. Interestingly, lithium also significantly protects
cultured neurons from AL-induced cell death. These results raise
the possibility of using chronic lithium treatment for the therapy
of Alzheimer’s disease.
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Key words: Alzheimer’s disease; Amyloid-L ; Cell death;
Glycogen synthase kinase-3; Lithium; Rat cortical neuron
1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder in
which the loss of neurons in certain brain regions including
the cortex and hippocampus is associated with the presence of
two distinct types of ¢brillar deposits, amyloid plaques and
neuro¢brillary tangles [1,2]. Amyloid deposits are mainly con-
stituted of the L-amyloid peptide (AL), a 39^43-amino acid
peptide which is a fragment of an integral membrane protein
referred to as the amyloid precursor protein (APP) [3]. Neuro-
¢brillary tangles contain hyperphosphorylated tau protein as
a major component and are also found in other neurodege-
nerative diseases [4].
A crucial role for AL in AD is strongly suggested as certain
mutations in the gene encoding APP which are causally linked
to some early-onset familial forms of the disease give rise to
increased AL levels [3]. Animal and cell culture studies also
support the view that accumulation of aggregated AL may
lead to neurodegeneration. The overexpression of a mutant
APP in a transgenic mouse leads to a massive amyloid depo-
sition which is accompanied by increased tau protein phos-
phorylation and neuronal cell death [5,6]. The microinjection
of ¢brillar aggregates of synthetic AL into the aged rhesus
monkey cerebral cortex also results in tau protein hyperphos-
phorylation and neuronal loss [7]. Furthermore, synthetic AL
induces cell death when added to primary cultures of rodent
cortical and hippocampal neurons [8^13]. Interestingly, the
phosphorylation of tau protein is also enhanced by the treat-
ment of cultured neurons with ¢brillar aggregates of AL
[9,14,15].
Tau is a microtubule-associated protein presumably in-
volved in the stabilization of axonal microtubules [16]. Hyper-
phosphorylation of tau protein appears to be an early event
preceding the formation of neuro¢brillary tangles in the
brains of AD patients [17]. As mentioned above, increased
tau phosphorylation has also been observed both in animal
models of AD [5,7] and in cultured neurons treated with AL
[9,14,15]. It has been hypothesized that tau hyperphospho-
rylation might lead to microtubule destabilization and tau
protein aggregation, thus causing a de¢cit of axonal transport
which could eventually result in neuronal cell death [4,16,18].
According to this view, the protein kinases responsible for
AL-induced tau protein hyperphosphorylation should be con-
sidered potentially interesting targets for therapeutic interven-
tion in AD.
We have recently reported that lithium blocks the phos-
phorylation of a number of sites on the tau molecule under
physiological conditions both in cultured neurons and in vivo
in rat brain [19]. Assuming that lithium behaves as a speci¢c
inhibitor of glycogen synthase kinase-3 (GSK-3) under the
conditions used in these assays [19^21], GSK-3 appears to
be a tau kinase in normal brain. Here we have investigated
the e¡ects of lithium on the AL-induced tau protein phospho-
rylation and cell death in primary cultures of rat cortical
neurons.
2. Materials and methods
2.1. Materials
Tau monoclonal antibodies 7.51 [22] (a kind gift of Dr. C. Wischik,
MRC, Cambridge, UK), Tau-1 [23] (a kind gift of Dr. L. Binder,
MGC, Illinois, USA) and PHF-1 [24] (a kind gift of Dr. P. Davies,
Albert Einstein College, Bronx, NY, USA) were used. All these anti-
bodies react with both human and rat tau proteins [22^24]. According
to the residue numbering of the longest human tau isoform of
441 amino acids [25], antibody Tau-1 recognizes tau protein only
when serines 195, 198, 199 and 202 are dephosphorylated [26] and
antibody PHF-1 recognizes tau when serines 396 and 404 are phos-
phorylated [27].
Synthetic human 40-amino acid L-amyloid peptide (AL1ÿ40) was
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purchased from QCB (Quality Controlled Biochemicals, Inc.). The
AL1ÿ40 peptide was dissolved in double distilled water at 1 mg/ml
and incubated at 37‡C for 7 days to preaggregate the peptide into a
largely ¢brillar form. Calcein acetoxymethyl ester (calcein AM) was
purchased from Molecular Probes (Eugene, OR, USA). All other
reagents were purchased from Sigma (St. Louis, MO, USA)
2.2. Neuronal culture
Cortical neuronal cultures were prepared from 18-day-old Wistar
rat embryos essentially as previously described [28,29]. Cerebral cor-
tices were enzymatically dissociated in phosphate-bu¡ered saline
(PBS) containing 1% bovine serum albumin, 0.4 mg/ml papain, and
6 mM glucose. Dissociated cells were collected by centrifugation
(800Ug, 5 min) and resuspended in medium supplemented with
20% horse serum. Culture medium consists of minimal essential me-
dium (MEM), 1% glutamax-I (Gibco, Grand Island, NY, USA) and
the components of B18 supplement [30] omitting glutamate, gluta-
mine, retinol, retinyl acetate, catalase, superoxide dismutase, and triio-
dothyronine. The cells were then plated at 1U105 cells/cm2 on plastic
or glass coverslips pretreated for 2^3 days with 10 WM poly-L-lysine
and for 2 h with laminin (1.38 Wg/ml). The 20% horse serum-contain-
ing medium was replaced after 3 h by 5% horse serum-containing
medium. After 2 days in vitro, cultures were switched to serum-free
de¢ned medium, two thirds of which was replaced every second day.
The experiments were performed after 7 or 9 days in vitro. Under our
culture conditions, neurons represented 86% of the cell population,
astrocytes 7.5% and microglial cells were hardly detectable [29].
2.3. Neuronal viability assays
For AL toxicity experiments, cultures were shifted to serum-free
MEM supplemented with N2 components [31], and neurons were
exposed to AL for di¡erent times. Cell viability was assessed by cal-
cein/propidium iodide uptake [32]. Calcein AM is taken up and
cleaved by esterases present within living cells yielding yellowish-green
£uorescence, whereas propidium iodide (PI) is only taken up by dead
cells which become orange-red £uorescent. In brief, neurons were
incubated for 30 min with 2 WM PI (Sigma) and 1 WM calcein-AM
(Molecular Probes). Then, the cultures were rinsed three times with
HBSS containing 2 mM CaCl2 and the cells were visualized by £uo-
rescence microscopy using a Zeiss Axiovert 135 microscope. Three
¢elds (selected at random) were analyzed per well (approximately
300 cells/¢eld) in at least three di¡erent experiments. Cell death was
expressed as percentage of PI-positive cells from the total number of
cells. In every experiment, speci¢c AL-induced cell death was obtained
after subtracting the number of dead cells present in vehicle-treated
cultures.
2.4. Protein preparation, gel electrophoresis and immunoblot analyses
Cells (106 cells for each experimental point) were harvested by
scraping, washed in chilled PBS, resuspended and homogenized in a
bu¡er consisting of 20 mM HEPES, pH 7.4, 100 mM NaCl, 100 mM
NaF, 1 mM sodium orthovanadate, 5 mM EDTA, and protease in-
hibitors (2 mM phenylmethylsulfonyl £uoride, 10 Wg/ml aprotinin,
10 Wg/ml leupeptin and 10 Wg/ml pepstatin). Lysates were centrifuged
at 10 000Ug for 10 min at 4‡C. The resulting supernatants were col-
lected and their protein contents determined by the bicinchoninic acid
(BCA) assay.
Samples were mixed with Laemmli bu¡er, boiled for 3 min, sepa-
rated by gel electrophoresis in the presence of sodium dodecyl sulfate
(SDS) on 12% resolving gels and transferred to nitrocellulose accord-
ing to standard procedures. A blocking bu¡er of 5% non-fat pow-
dered milk in PBS with 0.1% Tween-20 was used for all incubations.
Monoclonal antibodies to tau protein were obtained as hybridoma-
conditioned culture media and used at a dilution of 1/10. Immuno-
reactive proteins were visualized by the use of a peroxidase-conjugated
anti-mouse antibody and enhanced chemiluminescence detection
(Amersham). Quanti¢cation of immunoreactivity was performed by
densitometric scanning. Individual tau bands may include multiple
distinct tau proteins (arising from alternative splicing and di¡erential
phosphorylation) that comigrate and were therefore not quantitated
separately. Thus, total immunoreactivity for all tau bands was quan-
titated for each lane of immunoblots. The densitometry values ob-
tained for blots corresponding to the antibodies recognized phospho-
rylation-sensitive epitopes (Tau-1 and PHF-1) were normalized with
respect to the values obtained for antibody 7.51 which reacts with a
phosphorylation-independent epitope.
3. Results
3.1. L-Amyloid peptide induces an early increase in tau protein
phosphorylation which is followed by neuronal cell death
The e¡ect of ¢brillar AL1ÿ40 on the in situ phosphorylation
state of tau protein was analyzed by immunoblotting of cell
extracts with antibodies which react with phosphorylation-
sensitive epitopes as previously described [19]. Fig. 1A shows
that the treatment of cultured rat cortical neurons with 25 WM
AL1ÿ40 augments the immunoreactivity of tau protein to anti-
body PHF-1, which recognizes a phosphorylated epitope, with
respect to the immunoreactivity to antibody 7.51, which reacts
with a phosphorylation-independent epitope. This indicates
that AL enhances the phosphorylation of tau protein at the
epitope recognized by antibody PHF-1. The augmented phos-
phorylation of tau is observed as early as 1 h after the addi-
tion of AL and attains its maximal level after 3 h of treatment.
In addition to this enhancement in tau phosphorylation, a less
important but reproducible increase in the immunoreactivity
of tau protein to antibody 7.51 is also seen after 6 h of AL
treatment (see Fig. 1A, upper panel). This suggests that not
only the phosphorylation but also the total level of tau pro-
tein is increased within neurons incubated with AL, which
agrees well with previous observations [9,33].
The neurotoxicity of the treatment of cultured rat cortical
neurons with 25 WM AL1ÿ40 was also studied. Fig. 1B shows
that AL1ÿ40 induces a speci¢c death of cultured neurons which
is clearly observed after 24 h of treatment. Neurotoxicity was
also observed with a shorter fragment of AL, referred to as
AL25ÿ35, whereas scrambled peptides lack any neurotoxic ef-
fect [34]. AL-induced neuronal cell death was not attenuated
Fig. 1. L-Amyloid peptide enhances tau protein phosphorylation
and induces cell death in cultured rat cortical neurons. A: Neurons
were cultured for 9 days in vitro and then treated with 25 WM
AL1ÿ40 at the times indicated (1, 3 and 6 h). Cell extracts were pre-
pared, electrophoresed, blotted and probed with antibodies 7.51 and
PHF-1. Upper panels show the corresponding blots. ‘C’ refers to
untreated (control) neurons. Lower diagram represents the immu-
noreactivity of tau protein to antibody PHF-1, which reacts with a
phosphorylated epitope, as densitometry values normalized with re-
spect to the immunoreactivities to antibody 7.51 which recognizes a
phosphorylation-independent epitope. The PHF-1 normalized signal
is a measure of the state of phosphorylation of tau protein at the
PHF-1 epitope. B: Neurons were cultured for 7^9 days in vitro and
then treated with either 25 WM AL1ÿ40 or vehicle at the times indi-
cated (3, 24 and 96 h). Percentages of speci¢c AL-induced cell death
were determined by calcein/propidium iodide uptake as described in
Section 2. The data represent mean values þ S.E.M. of n = 4 di¡erent
experiments performed in triplicate.
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by cotreatment with 3 WM MK-801 (data not shown), which is
a speci¢c antagonist of NMDA-type glutamate receptors.
Thus, in our culture conditions, AL-induced neuronal death
does not involve glutamate excitotoxicity. Interestingly, no
AL-induced neuronal cell death was observed 3 h after the
addition of AL, when the maximal phosphorylation of tau is
detected (compare Fig. 1A and B). These data indicate that
the increased tau protein phosphorylation observed in AL-
treated neurons is an early event occurring before cell
death.
3.2. Lithium prevents the L-amyloid-induced enhancement of
tau protein phosphorylation in cultured neurons
To examine whether lithium a¡ects the increase in tau pro-
tein phosphorylation triggered by AL, the phosphorylation of
tau protein was analyzed by immunoblotting with antibodies
Tau-1, which recognizes a phosphorylatable epitope only
when it is not phosphorylated, and PHF-1, which reacts
with a phosphorylated epitope. Fig. 2 shows that treatment
of cultured neurons with 10 mM LiCl for 3 h resulted in an
increased Tau-1 and a decreased PHF-1 immunoreactivities,
which is consistent with a net dephosphorylation of tau pro-
tein at both epitopes. In contrast, treatment of cultured neu-
rons with 25 WM AL1ÿ40 for 3 h resulted in a decreased Tau-1
and an increased PHF-1 immunoreactivity, which indicates an
enhanced phosphorylation of tau protein at both epitopes.
When neurons were treated with AL in the presence of 10
mM LiCl, the increase in PHF-1 and the decrease in Tau-1
immunoreactivities were abolished. Accordingly, no enhance-
ment of tau protein phosphorylation occurred in cultured
neurons treated with AL in the presence of lithium.
3.3. Lithium protects cultured neurons from L-amyloid-induced
cell death
Since lithium blocks an early event triggered by AL, its
consequences on AL-induced neurodegeneration were also ex-
amined. Fig. 3 shows that treatment with 25 WM AL1ÿ40 re-
sults in 18.06 þ 1.69% cell death 24 h later. However, only
3.4 þ 1.81% cell death is observed when cultured neurons are
treated with AL in the presence of 10 mM lithium, which
indicates a 81.1% protection (see Fig. 3E). Thus, lithium sig-
ni¢cantly protects cultured neurons against AL neurotoxicity.
Moreover, the neuroprotective e¡ect of lithium does not
seem to be merely due to a delay in neuronal cell death as
it is still observed 4 days after AL treatment. At this time, AL
treatment of cultured neurons brings about 27.7 þ 2% cell
death, which is reduced to 9.85 þ 3.2% in the presence of
2 mM LiCl and 500 WM myo-inositol, thus indicating a
64.4% protection (see Fig. 3F). Approximately the same level
of neuronal cell death is observed in cultured neurons treated
with 2 mM LiCl and 500 WM myo-inositol either in the pres-
Fig. 3. Lithium protects cultured rat cortical neurons against L-amy-
loid peptide-induced cell death. Neurons were cultured for 9 days in
vitro and then treated with 25 WM AL (A and B) or 25 WM AL in
the presence of 10 mM LiCl (C and D) for 24 h. Viable and dead
cells were stained with calcein AM and propidium iodide as de-
scribed in Section 2 and photographed at a £uorescence microscope.
Shown are viable (A and C) and dead (B and D) cells in each treat-
ment. Percentages of speci¢c AL-induced cell death were determined
after 24 h (E) as described in Section 2. The data represent mean
values þ S.E.M. of n = 3 di¡erent experiments performed in tripli-
cate; ***P6 0.0005 (t-test). Neurons were cultured for 7 days in vi-
tro and then treated with with 25 WM AL (AL) or treated with
25 WM AL in the presence of 2 mM LiCl and 0.5 mM myo-inositol
(AL+LiCl+Ino) for 96 h. Percentages of speci¢c cell death were de-
termined as described in Section 2 (F). The data represent mean val-
ues þ S.E.M. of n = 2 di¡erent experiments performed in triplicate;
**P6 0.005 (t-test).
Fig. 2. Lithium prevents L-amyloid peptide-induced tau protein
phosphorylation in cultured rat cortical neurons. Neurons were cul-
tured for 9 days in vitro and then treated with vehicle (C), 10 mM
LiCl (Li), 25 WM AL (AL) or 25 WM AL in the presence of 10 mM
LiCl (AL+Li) for 2 h. Cell extracts were prepared, electrophoresed,
blotted and probed with antibodies 7.51, Tau-1 and PHF-1. Panels
show the blots corresponding to a typical experiment. The immu-
noreactivities of tau protein to antibodies Tau-1, which recognizes a
phosphorylatable epitope only when it is not phosphorylated, and
PHF-1, which reacts with a phosphorylated epitope, were quanti-
tated as densitometry values which were normalized with respect to
the immunoreactivities to antibody 7.51, which recognizes a phos-
phorylation-independent epitope. Lower right diagram represents
the mean values and standard deviations (n = 3) of the normalized
signals for antibodies Tau-1 and PHF-1.
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ence or in the absence of AL. We used 2 mM instead of 10
mM LiCl because less neuronal cell death was observed after
4 days. It seems therefore that the prolonged treatment of
cultured neurons with lithium is slightly toxic to neurons
and neurotoxicity is still increased when inositol is omitted
(data not shown). This suggests that the depletion of intra-
cellular inositol is presumably important for lithium neuro-
toxicity. Despite its slight neurotoxicity during prolonged
treatment, lithium is still neuroprotective against AL-induced
neuronal cell death at a concentration similar to that attained
clinically (see Fig. 3F).
4. Discussion
Addition of ¢brillar AL to cultured neurons mimics certain
key aspects of neurodegeneration in AD [1]. For this reason,
AL-treated neuronal cultures are currently employed not only
to analyze the molecular mechanisms of AL-induced neuronal
cell death but also to screen for novel neuroprotective agents
[34,35]. In this context, we report here that lithium prevents
the AL-induced increase in tau protein phosphorylation and
signi¢cantly inhibits the death of cultured neurons triggered
by AL. These e¡ects of lithium were observed even in the
presence of extracellular inositol, suggesting that they are
not due to depletion of intracellular inositol [36]. Indeed, a
prolonged treatment of cultured neurons with lithium results
in some loss of cell viability, which is reduced by increasing
the extracellular inositol concentration. Accordingly, deple-
tion of cellular inositol occurring after inositol monophospha-
tase inhibition by lithium [37] appears to be toxic for neurons
rather than neuroprotective under our culture conditions.
Taken together, these results are consistent with the hy-
pothesis that GSK-3, the putative target for lithium [19^
21,38], is involved in the neuropathological cascade triggered
by AL. The role of GSK-3 in tau protein phosphorylation in
AD was previously suggested by the colocalization of one
isoform of this kinase (GSK-3L) with hyperphosphorylated
tau within the brains of AD patients [39]. Furthermore, a
recent report has shown that GSK-3L antisense oligonucleo-
tides inhibit the enhanced phosphorylation of tau protein
which is induced by a 10-amino acid fragment of AL referred
to as AL25ÿ35 in cultured rat hippocampal neurons [15]. How-
ever, the implication of other protein kinases in AL-induced
tau protein hyperphosphorylation cannot be excluded. In fact,
tau protein also becomes hyperphosphorylated in AD at some
sites on the molecule which do not seem to be targeted by
GSK-3 [16].
Interestingly, lithium not only blocked AL-induced tau pro-
tein phosphorylation but also inhibited AL neurotoxicity.
These lithium e¡ects parallel those of insulin and insulin-like
growth factor 1 (IGF-1). It has been demonstrated that IGF-1
receptor activation decreases tau protein phosphorylation in a
neuronal-like cell line through the inhibition of GSK-3 via the
phosphatidylinositol 3-kinase/protein kinase B signaling path-
way [40]. Moreover, IGF-1 also protects cultured neurons
against amyloid-induced toxicity [35]. Thus, both lithium
and IGF-1 are able to inhibit GSK-3, prevent tau phospho-
rylation and protect from AL neurotoxicity. However, we
cannot fully rule out the possibility that both IGF-1 and
lithium treatments modify an additional unknown target
which could be implicated in AL-induced neurodegeneration.
Even if we assume that GSK-3 is the relevant target for both
IGF-1 and lithium, this does not necessarily mean that tau
protein phosphorylation is required for AL-induced neuronal
cell death. The phosphorylation of other proteins in addition
to tau may be involved in the activation of a cell death pro-
gram by GSK-3. In fact, GSK-3 is a multifunctional kinase
which modi¢es many metabolic regulatory enzymes, cyto-
skeletal proteins and transcription factors [41]. For instance,
it has been suggested that the phosphorylation of pyruvate
dehydrogenase by GSK-3 may cause mitochondrial dysfunc-
tion which might bring about neuronal cell death [42]. In any
case, GSK-3 might be a crucial element in the AL-triggered
molecular cascade leading to neurodegeneration. As lithium
treatment does not confer complete protection against AL
neurotoxicity, it is possible that other intracellular mediators
which are not downstream of GSK-3 may also contribute to
AL-induced neurodegeneration. Alternatively, partial protec-
tion may arise from side e¡ects of lithium acting on other
targets in addition to GSK-3 as mentioned above.
Of importance in this regard is the fact that similar neuro-
protective e¡ects of lithium on cultured neurons subjected to
di¡erent insults, including suboptimal culture conditions [43-
45] and glutamate excitotoxicity [46], have been demonstrated.
Whether GSK-3 is the relevant target for lithium in all these
cases remains to be established. Supportive of this view is the
fact that the overexpression of GSK-3L causes apoptosis,
whereas the overexpression of a dominant-negative GSK-3L
mutant prevents the apoptosis which is induced following in-
hibition of phosphatidylinositol 3-kinase in some cell lines
[47].
In view of these data, it is tempting to speculate that a
chronic low-dose lithium treatment similar to that prescribed
for manic-depressive patients [48,49] might also be useful to
curb neuronal cell death in AD and possibly in other neuro-
degenerative disorders.
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